Exclusive Online Content
XOMA Acquires Royalty & Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon
XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay….
RxCelerate Acquires Methuselah Health & Launches ProQuant World-Beating Proteomics Service
Next-generation proteomics technology made available to the biotech and pharmaceutical industry through the acquisition of Methuselah Health by leading R&D services provider, RxCelerate….
Evaxion Announces Promising Results From Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy
Evaxion Biotech A/S recently announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02….
Attralus & Ossianix Announce Option & License Agreement Using the TXP1 Brain Shuttle for Targeted Delivery of a Pan-Amyloid Removal Therapeutic for Neurodegenerative Disorders
Attralus, Inc. and Ossianix recently announced they have entered into a definitive agreement using Ossianix’ brain shuttle technology to enhance the targeted delivery of novel….
Meridian Medical Technologies & Kindeva Drug Delivery to Combine
Meridian Medical Technologies recently announced it will combine with Kindeva Drug Delivery to create a leading global drug-device combination product Contract Development and….
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunities….
Key Patent Issued on Eligo’s Gene-Editing Breakthroughs Applied to Skin Disorders
Eligo Bioscience recently announced the issuance by the USPTO of the first patent in a wide family covering genetic engineering of a key skin microbiome species, Cutibacterium acnes, to support….
Indivior PLC to Acquire Opiant Pharmaceuticals
Opiant Pharmaceuticals Inc. recently announced it has entered into a definitive merger agreement to be acquired by Indivior Inc, a subsidiary of Indivior PLC (LON: INDV). Under the terms of the agreement,….
IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines….
Minoryx & Neuraxpharm Announce Strategic Alliance to Provide New Therapy for Rare CNS Disease
The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD)….
EXCLUSIVE ONLINE CONTENT
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….
Kincell Bio & Imugene Announce Strategic Manufacturing & Process Development Partnership
Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over 3 years….
Cullinan Therapeutics Announces Strategic Expansion Into Autoimmune Diseases & $280-Million Private Placement
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication….
BC Platforms & NTT Group Announce Official Opening Ceremony for Exclusive Collaboration & Launch of Japanese Precision Medicine Platform
BC Platforms (BCP) recently announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven….